Possis Medical answers FDA questions
This article was originally published in Clinica
Possis Medical says it has submitted supplementary data on its AngioJet thrombectomy catheter to the US FDA. Possis submitted a 510(k) for peripheral artery applications in March, but only used data from the first 86 patients out of a full cohort of 130. However, the FDA insisted that it should receive either the full data set or proof that 86 patients were sufficient to demonstrate the safety of AngioJet (see Clinica No 712, p 19). Possis spokesman Robert Dutcher says the company now has clinical data (which compares AngioJet to the Fogarty embolectomy catheter) for all 130 patients and has submitted it to the agency.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.